Factors related to post-treatment relapse in chronic hepatitis B patients who lost HBeAg after lamivudine therapy

Kwan Soo Byun, Oh Sang Kwon, Ju Hyun Kim, Hyung Joon Yim, Yun Jung Chang, Jin Yong Kim, Jong Eun Yeon, Jong Jae Park, Jae Seon Kim, Young-Tae Bak, Chang Hong Lee

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background and Aims: It is uncertain if a patient's lamivudine response after HBeAg loss is durable. In Korean chronic hepatitis B patients, the relapse rate is high after termination of lamivudine therapy for patients with HBeAg loss. We evaluated the factors related to relapse in chronic hepatitis B patients with HBeAg loss after lamivudine therapy. Methods: A total of 132 chronic hepatitis B patients, who initially had HBeAg and did not have decompensated features, were analyzed in this study. These patients lost the HBeAg after lamivudine therapy and then their therapy was stopped. Post-treatment serum alanine aminotransferase (ALT), HBeAg, anti-HBe and hepatitis B virus (HBV) DNA were monitored until relapse. Results: Seventy-five patients relapsed (cumulative relapse rate: 56% at 6 months). Upon univariate analysis, the factors of age, serum total bilirubin, presence of anti-HBe after HBeAg loss, and the duration of additional lamivudine therapy after HBeAg loss were associated with relapse. Upon multivariate analysis, older age, a higher serum total bilirubin and the shorter duration of additional lamivudine therapy were significant risk factors for relapse. Patterns of relapse were the re-elevation of ALT, re-emergence of HBV DNA (69 patients) and reappearance of HBeAg (55 patients). Conclusions: To prevent relapse in patients with chronic hepatitis B infection after lamivudine therapy, age and serum bilirubin level of patients as well as a prolonged duration of additional lamivudine therapy should be considered.

Original languageEnglish
Pages (from-to)1838-1842
Number of pages5
JournalJournal of Gastroenterology and Hepatology (Australia)
Volume20
Issue number12
DOIs
Publication statusPublished - 2005 Jan 1

Fingerprint

Lamivudine
Hepatitis B e Antigens
Chronic Hepatitis B
Recurrence
Bilirubin
Therapeutics
Serum
Alanine Transaminase
Hepatitis B virus
Age Factors
DNA
Multivariate Analysis

Keywords

  • Chronic hepatitis B
  • Lamivudine
  • Relapse

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Factors related to post-treatment relapse in chronic hepatitis B patients who lost HBeAg after lamivudine therapy. / Byun, Kwan Soo; Kwon, Oh Sang; Kim, Ju Hyun; Yim, Hyung Joon; Chang, Yun Jung; Kim, Jin Yong; Yeon, Jong Eun; Park, Jong Jae; Kim, Jae Seon; Bak, Young-Tae; Lee, Chang Hong.

In: Journal of Gastroenterology and Hepatology (Australia), Vol. 20, No. 12, 01.01.2005, p. 1838-1842.

Research output: Contribution to journalArticle

@article{b9dd7f32c77844bb99ffbebf15de9c28,
title = "Factors related to post-treatment relapse in chronic hepatitis B patients who lost HBeAg after lamivudine therapy",
abstract = "Background and Aims: It is uncertain if a patient's lamivudine response after HBeAg loss is durable. In Korean chronic hepatitis B patients, the relapse rate is high after termination of lamivudine therapy for patients with HBeAg loss. We evaluated the factors related to relapse in chronic hepatitis B patients with HBeAg loss after lamivudine therapy. Methods: A total of 132 chronic hepatitis B patients, who initially had HBeAg and did not have decompensated features, were analyzed in this study. These patients lost the HBeAg after lamivudine therapy and then their therapy was stopped. Post-treatment serum alanine aminotransferase (ALT), HBeAg, anti-HBe and hepatitis B virus (HBV) DNA were monitored until relapse. Results: Seventy-five patients relapsed (cumulative relapse rate: 56{\%} at 6 months). Upon univariate analysis, the factors of age, serum total bilirubin, presence of anti-HBe after HBeAg loss, and the duration of additional lamivudine therapy after HBeAg loss were associated with relapse. Upon multivariate analysis, older age, a higher serum total bilirubin and the shorter duration of additional lamivudine therapy were significant risk factors for relapse. Patterns of relapse were the re-elevation of ALT, re-emergence of HBV DNA (69 patients) and reappearance of HBeAg (55 patients). Conclusions: To prevent relapse in patients with chronic hepatitis B infection after lamivudine therapy, age and serum bilirubin level of patients as well as a prolonged duration of additional lamivudine therapy should be considered.",
keywords = "Chronic hepatitis B, Lamivudine, Relapse",
author = "Byun, {Kwan Soo} and Kwon, {Oh Sang} and Kim, {Ju Hyun} and Yim, {Hyung Joon} and Chang, {Yun Jung} and Kim, {Jin Yong} and Yeon, {Jong Eun} and Park, {Jong Jae} and Kim, {Jae Seon} and Young-Tae Bak and Lee, {Chang Hong}",
year = "2005",
month = "1",
day = "1",
doi = "10.1111/j.1440-1746.2005.03952.x",
language = "English",
volume = "20",
pages = "1838--1842",
journal = "Journal of Gastroenterology and Hepatology (Australia)",
issn = "0815-9319",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - Factors related to post-treatment relapse in chronic hepatitis B patients who lost HBeAg after lamivudine therapy

AU - Byun, Kwan Soo

AU - Kwon, Oh Sang

AU - Kim, Ju Hyun

AU - Yim, Hyung Joon

AU - Chang, Yun Jung

AU - Kim, Jin Yong

AU - Yeon, Jong Eun

AU - Park, Jong Jae

AU - Kim, Jae Seon

AU - Bak, Young-Tae

AU - Lee, Chang Hong

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Background and Aims: It is uncertain if a patient's lamivudine response after HBeAg loss is durable. In Korean chronic hepatitis B patients, the relapse rate is high after termination of lamivudine therapy for patients with HBeAg loss. We evaluated the factors related to relapse in chronic hepatitis B patients with HBeAg loss after lamivudine therapy. Methods: A total of 132 chronic hepatitis B patients, who initially had HBeAg and did not have decompensated features, were analyzed in this study. These patients lost the HBeAg after lamivudine therapy and then their therapy was stopped. Post-treatment serum alanine aminotransferase (ALT), HBeAg, anti-HBe and hepatitis B virus (HBV) DNA were monitored until relapse. Results: Seventy-five patients relapsed (cumulative relapse rate: 56% at 6 months). Upon univariate analysis, the factors of age, serum total bilirubin, presence of anti-HBe after HBeAg loss, and the duration of additional lamivudine therapy after HBeAg loss were associated with relapse. Upon multivariate analysis, older age, a higher serum total bilirubin and the shorter duration of additional lamivudine therapy were significant risk factors for relapse. Patterns of relapse were the re-elevation of ALT, re-emergence of HBV DNA (69 patients) and reappearance of HBeAg (55 patients). Conclusions: To prevent relapse in patients with chronic hepatitis B infection after lamivudine therapy, age and serum bilirubin level of patients as well as a prolonged duration of additional lamivudine therapy should be considered.

AB - Background and Aims: It is uncertain if a patient's lamivudine response after HBeAg loss is durable. In Korean chronic hepatitis B patients, the relapse rate is high after termination of lamivudine therapy for patients with HBeAg loss. We evaluated the factors related to relapse in chronic hepatitis B patients with HBeAg loss after lamivudine therapy. Methods: A total of 132 chronic hepatitis B patients, who initially had HBeAg and did not have decompensated features, were analyzed in this study. These patients lost the HBeAg after lamivudine therapy and then their therapy was stopped. Post-treatment serum alanine aminotransferase (ALT), HBeAg, anti-HBe and hepatitis B virus (HBV) DNA were monitored until relapse. Results: Seventy-five patients relapsed (cumulative relapse rate: 56% at 6 months). Upon univariate analysis, the factors of age, serum total bilirubin, presence of anti-HBe after HBeAg loss, and the duration of additional lamivudine therapy after HBeAg loss were associated with relapse. Upon multivariate analysis, older age, a higher serum total bilirubin and the shorter duration of additional lamivudine therapy were significant risk factors for relapse. Patterns of relapse were the re-elevation of ALT, re-emergence of HBV DNA (69 patients) and reappearance of HBeAg (55 patients). Conclusions: To prevent relapse in patients with chronic hepatitis B infection after lamivudine therapy, age and serum bilirubin level of patients as well as a prolonged duration of additional lamivudine therapy should be considered.

KW - Chronic hepatitis B

KW - Lamivudine

KW - Relapse

UR - http://www.scopus.com/inward/record.url?scp=33644878638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644878638&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1746.2005.03952.x

DO - 10.1111/j.1440-1746.2005.03952.x

M3 - Article

C2 - 16336441

AN - SCOPUS:33644878638

VL - 20

SP - 1838

EP - 1842

JO - Journal of Gastroenterology and Hepatology (Australia)

JF - Journal of Gastroenterology and Hepatology (Australia)

SN - 0815-9319

IS - 12

ER -